Analysts Just Made A Massive Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
Analysts Just Made A Massive Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
Gossamer Bio, Inc. (NASDAQ:GOSS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.
Gossamer Bio,Inc.(纳斯达克股票代码:GOSS)股东今天会有理由微笑,分析师大幅度提高了今年的预测。分析师大大增加了其收入预测,表明了业务基本面的明显改善。
Following the upgrade, the most recent consensus for Gossamer Bio from its nine analysts is for revenues of US$133m in 2024 which, if met, would be a huge 38% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 32% to US$0.24. Yet before this consensus update, the analysts had been forecasting revenues of US$100m and losses of US$0.41 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
在升级后,来自九位分析师对Gossamer Bio的最新共识是,该公司2024年的营业收入预计为1.33亿美元,如果实现,将比过去一年的销售额增长38%。每股亏损预计在不远的将来会大大降低,收窄32%至0.24美元。但在此共识更新之前,分析师们预测2024年的营业收入为1.00亿美元,每股亏损为0.41美元。所以在最近的共识更新之后,看法出现了相当大的变化,分析师们大幅增加了他们的收入预测,同时随着业务朝着盈亏平衡的方向发展,估计的亏损也有所减少。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240814/0-e50199a19e139d4b6440e1e14d3fe7d7-0-3a0ed0c9c2ee118159b44168e14fcc53.png/big)
Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 91% growth on an annualised basis. That is in line with its 109% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 23% annually. So it's pretty clear that Gossamer Bio is forecast to grow substantially faster than its industry.
当然,观察这些预测的另一种方法是将它们放置于行业背景中。分析师表示,到2024年底,营业收入预计按年计算将增长91%,这与过去五年增长109%的年增长率相一致。与整个行业相比,分析师的预测(总体)表明其收入每年增长23%。因此,很明显,Gossamer Bio的增长速度预计将快得多,超过行业板块。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Gossamer Bio's prospects. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. More bullish expectations could be a signal for investors to take a closer look at Gossamer Bio.
这里最重要的是,分析师降低了今年的每股亏损预测,反映了他们对Gossamer Bio前景的增加乐观情绪。他们还升级了今年的营业收入预测,销售额预计将比市场整体增长更快。更看好的预期可能是投资者更加关注Gossamer Bio的信号。
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple Gossamer Bio analysts - going out to 2026, and you can see them free on our platform here.
即使如此,公司的长期轨迹对于股东的价值创造更为重要。我们收集了多位Gossamer Bio分析师到2026年的估计,您可以在我们的平台上免费查阅。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
当然,看到公司高管将大量资金投入股票与分析师是否升级他们的估计同样有用。因此,您可能还希望搜索此高内部持股的股票免费名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。